載入中
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
前收盤價
US$1.90
−US$0.10 · -5.00%
盤中時間採用ET。市場資料可能有所延遲。
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
日內區間
目前US$1.90
52週區間
目前US$1.90
盤中時間採用ET。市場資料可能有所延遲。
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
日內區間
目前US$1.90
52週區間
目前US$1.90
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 40.82萬 USD | 67.4萬 USD | 74.3萬 USD | 81萬 USD | 85.3萬 USD |
| 銷貨成本 | 2.42萬 USD | — | — | — | — |
| 毛利 | 38.4萬 USD | 67.4萬 USD | 74.3萬 USD | 81萬 USD | 85.3萬 USD |
| 研究與開發 | 674.61萬 USD | 575.7萬 USD | 598.3萬 USD | 776.3萬 USD | 985萬 USD |
| 銷售、一般及管理費用 | 366.69萬 USD | 304.7萬 USD | 295.5萬 USD | 314.3萬 USD | 384.5萬 USD |
| 營業費用 | 1041.3萬 USD | 880.4萬 USD | 893.8萬 USD | 1090.6萬 USD | 1369.5萬 USD |
| 利息收入 | 28.63萬 USD | 29.1萬 USD | 50.6萬 USD | 22.2萬 USD | 2.4萬 USD |
| 利息支出 | 1.41萬 USD | 1.4萬 USD | 1.4萬 USD | 7.7萬 USD | 1.8萬 USD |
| 折舊和攤銷 | 2.42萬 USD | 7000 USD | 1.5萬 USD | 1.4萬 USD | 1.4萬 USD |
| 營業利益 | −1002.89萬 USD | −813萬 USD | −819.5萬 USD | −1009.6萬 USD | −1284.2萬 USD |
| 淨利 | −990.6萬 USD | −788萬 USD | −763.4萬 USD | −1017.3萬 USD | −1259.5萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.00
上漲空間 321.05%評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月5日 | 1:20 | — | — |
股票分割 | 2023年1月9日 | 1:10 | — | — |
股票分割 | 2019年5月10日 | 1:15 | — | — |
已生效 2026年1月5日
1:20
已生效 2023年1月9日
1:10
已生效 2019年5月10日
1:15
報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM171.97萬0.01%175.23億 USD0.07%US$52.21+1.32%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX48萬0.07%6.65億 USD0.65%US$71.64+1.00%
State Street SPDR S&P Emerging Asia Pacific ETFGMF33.09萬0.08%4.22億 USD0.49%US$154.60.00%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM9.44萬0.01%18.02億 USD0.09%US$87.44+0.55%State Street SPDR Portfolio Emerging Markets ETFSPEMState Street SPDR S&P Emerging Markets Small Cap ETFEWXState Street SPDR S&P Emerging Asia Pacific ETFGMFState Street SPDR Portfolio MSCI Global Stock Market ETFSPGMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
